Evaxion AS (EVAX) Q1 2025 Earnings Call Highlights: Strong Cash Position and Promising Vaccine ...

Evaxion AS (EVAX) Q1 2025 Earnings Call Highlights: Strong Cash Position and Promising Vaccine ...
Total equity has increased to EUR10.3 million, as reported at the end of 2024. The earnings call transcript provides more details. The EVX-01 vaccine mainly triggers CD4 T cells with some CD8 T cell response.